2010
DOI: 10.1038/labinvest.2009.119
|View full text |Cite
|
Sign up to set email alerts
|

Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine

Abstract: BackgroundExtracorporeal membrane oxygenation (ECMO) is a life-saving support system used in neonates and young children with severe cardiorespiratory failure. Although ECMO has reduced mortality in these critically-ill patients, almost all patients treated with ECMO develop a systemic inflammatory response syndrome (SIRS) characterized by a ‘cytokine storm’, leukocyte activation, and multisystem organ dysfunction. We used a neonatal porcine model of ECMO to investigate whether rising plasma concentrations of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

19
157
0
3

Year Published

2015
2015
2022
2022

Publication Types

Select...
4
4
1

Relationship

0
9

Authors

Journals

citations
Cited by 186 publications
(179 citation statements)
references
References 55 publications
19
157
0
3
Order By: Relevance
“…GI bleeding may be more frequent in ECLS patients as a result of multifactorial coagulopathy, generation of systemic inflammation, and nonpulsatile blood flow during VA ECLS, which can lead to reduced gastric perfusion and pH [2][3][4][5]. Future prospective studies would be helpful in confirming our findings.…”
supporting
confidence: 67%
“…GI bleeding may be more frequent in ECLS patients as a result of multifactorial coagulopathy, generation of systemic inflammation, and nonpulsatile blood flow during VA ECLS, which can lead to reduced gastric perfusion and pH [2][3][4][5]. Future prospective studies would be helpful in confirming our findings.…”
supporting
confidence: 67%
“…AKI) and considerable mortality [21]. As in other extracorporeal treatments, the blood shear stress [21], the exposure to non-self surfaces and the air/blood interface may cause a hypercoagulable state [16] as well as systemic inflammation (fig. 3) [22].…”
Section: Ecmo-related Variablesmentioning
confidence: 99%
“…However, in treating patients on ECLS, one of the challenges is understanding and appropriately compensating for the effect of the extracorporeal circuit on drug pharmacokinetics (PKs). Drug PKs can be altered in three primary ways: (i) adsorption of drug to the various components of the device;1, 2 (ii) increased volume of distribution due to hemodilution and physiologic changes associated with ECLS (e.g., inflammation);3, 4, 5 and (iii) altered clearance due to the underlying disease or direct impact of the artificial organ 6. As a result, optimal dosing in this setting likely differs compared to individuals not on ECLS.…”
mentioning
confidence: 99%